Tahara M, Greil R, Rischin D, Harrington KJ, Burtness B, de Castro G, Psyrri A, Braña I, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Ishak WZW, Lin J, Gumuscu B, Lerman N, Soulières D(2025) Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study Eur J Cancer, 221, 115395(in press) DOI 10.1016/j.ejca.2025.115395, PubMed 40262400
Eriksen JG, Maare C, Johansen J, Primdahl H, Bratland Å, Kristensen CA, Andersen M, Alsner J, Overgaard J, DAHANCA(2025) DAHANCA19: A randomized phase III study of primary curative (chemo)-radiotherapy and the EGFR-inhibitor zalutumumab for squamous cell carcinoma of the head and neck Radiother Oncol, 110899(in press) DOI 10.1016/j.radonc.2025.110899, PubMed 40258418
Thomassen D, Roychoudhury S, Amdal CD, Reynders D, Musoro JZ, Sauerbrei W, Goetghebeur E, le Cessie S, SISAQOL-IMI Work Package 3(2025) Handling missing values in patient-reported outcome data in the presence of intercurrent events BMC Med Res Methodol, 25(1), 56 DOI 10.1186/s12874-025-02510-8, PubMed 40025441